NASDAQ · Biotechnology · USD

Rallybio Corporation (RLYB) Stock Analysis

Rallybio Corporation (RLYB) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

RLYB

$16.22

−$0.16 (−0.98%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare RLYB with… →

RLYB Key Statistics

As of Oct 21, 2026

Trading

Open: $16.37
Previous Close: $16.38
Day's Range: 16.16–16.60
52-Week Range: 3.67–17.57
Volume: 13.64K
Beta: −0.71

Valuation

Market Cap: $86.17M
P/E Ratio: 2.02
P/S ratio: 133.39
EPS (ttm): 8.03

Financials (FY)

Revenue (FY): $858.00K+34.91%
Net Income (FY): −$8.98M
Profit margin: 7,051.24%
Shares Outstanding: 5.31M
1-Year Return: +262.05%

Dividend and dates

Avg Volume: 15.90K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, RLYB closed at $16.22, +262.05% over 1 year.

Rallybio Corporation (RLYB) has a market capitalization of $86.17M.

In fiscal 2025, RLYB reported revenue of $858.00K.

RLYB Stock Return by Calendar Year

Rallybio Corporation (RLYB) return since Jul 2021: what $10,000 became

1 year: $10,000 $36,205; +262.05%
5 years: $10,000 $1,270; −87.30%
Since Jul 2021: $10,000 $1,438; −85.62%

If you had invested $10,000 in Rallybio Corporation (RLYB) at the close on July 29, 2021, the earliest close on record here, it would have been worth $1,438 at the close on October 21, 2026: −85.62% in total, −30.99% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−32.34%−31.13%−63.62%−59.83%−28.54%+195.55%

2021*20222023202420252026*

Year	Return
2026 (partial year)	+195.55%
2025	−28.54%
2024	−59.83%
2023	−63.62%
2022	−31.13%
2021 (partial year)	−32.34%

As of October 21, 2026.

RLYB Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$858.00K	−$8.98M	−1,046.4%
2024	$636.00K	−$57.78M	−9,084.1%
2023	$0.00	−$74.56M	—
2022	$0.00	−$66.65M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$858.00K	—	−$33.06M	−$8.98M	−1,046.4%
2024	$636.00K	—	−$60.50M	−$57.78M	−9,084.1%
2023	$0.00	—	−$78.93M	−$74.56M	—
2022	$0.00	—	−$67.88M	−$66.65M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

RLYB Valuation vs Biotechnology Median

Median of 608 stocks

Metric	RLYB	Biotechnology median	vs median
P/E	2.02	16.60	0.1x the median
P/S ratio	133.39	13.30	10.0x the median
Profit margin	7,051.24%	−38.31%	7,089.5 pts above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Analysis

Data-derived

Company Overview

Rallybio Corporation (RLYB) is capitalised at $86.17M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 7 employees.

RLYB last closed at $16.22 on October 21, 2026. That is −$0.16 (−0.98%) against the previous close. The 52-week range on file runs from $3.67 to $17.57. The latest close sits 341.96% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $858.00K. Against the prior fiscal year total of $636.00K, that is a change of +34.91%. The same year closed with a net loss of $8.98M. The reported profit margin is 7,051.24%. That is 7,089.5 percentage points above the Biotechnology median of −38.31%. Trailing earnings per share are 8.03.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $858.00K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

On trailing earnings, the shares are priced at 2.02 times earnings. That is 0.1 times the Biotechnology median of 16.6. The price-to-sales ratio is 133.39. On price-to-sales that is 10 times the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year total return is +262.05%. Measured over 5 years, that is −33.82% a year compounded. The reported beta is −0.71. Annualized volatility over the trailing 5 years is 104.6%.

Growth & Income

No dividend is on file for RLYB.

So far in 2026 the total return is +195.55%. Across the complete calendar years on file, 2025 returned −28.54% and 2023 returned −63.62%. Of the 4 complete calendar years on file, 0 finished higher.

Peer Comparison

Rallybio Corporation (RLYB) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Rallybio Corporation	RLYB	$86.17M	2.0
Vertex Pharmaceuticals Incorporated	VRTX	$132.95B	30.4
Moderna, Inc.	MRNA	$98.14B	—
Regeneron Pharmaceuticals, Inc.	REGN	$82.95B	19.9

The Biotechnology industry average P/E ratio is 16.6x. Rallybio Corporation trades at a P/E of 2.0.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

MRNA

Moderna, Inc.

$98.14B

REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

ARGX

argenx SE

$55.97B

ONC

BeOne Medicines AG

$43.97B

RVMD

Revolution Medicines, Inc.

$41.64B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

JNJ

Johnson & Johnson

$621.22B

ABBV

AbbVie Inc.

$503.27B

UNH

UnitedHealth Group Incorporated

$374.30B

MRK

Merck & Co., Inc.

$369.78B

View all Healthcare stocks →

About Rallybio Corporation

Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.

Visit website →